Research
Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer
Nature · By Marina C. Garassino ·
The Brief
- Researchers developed and validated a computational pathology biomarker, the TROP2 normalized membrane ratio, which quantifies subcellular TROP2 localization.
- The source abstract reports that this ratio predicts improved progression-free survival and other outcomes with datopotamab deruxtecan in non-small-cell lung cancer.
- The study was published online in Nature Medicine on 11 November 2026.
Why it matters
If validated further, a pathology-based TROP2 membrane measurement could help identify non-small-cell lung cancer patients more likely to benefit from datopotamab deruxtecan.
Who’s affected
- clinicians and researchers in non-small-cell lung cancer
- pathologists and developers of computational pathology tools
- #lung cancer
- #biomarkers
- #computational pathology
- #antibody-drug conjugates
- #trop2
Nature Medicine, Published online: 11 November 2026; doi:10.1038/s41591-026-04716-9 This work developed and validated a computational pathology biomarker—the TROP2 normalized membrane ratio—that quantifies subcellular TROP2 localization and predicts improved progression-free and…
Timeline
Published online in Nature Medicine
nature.com
Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer